Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Jumped 10.6% Today

By Keith Speights - Jun 24, 2021 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is setting up a subsidiary to launch its COVID-19 test in Mexico.

What happened

Shares of Sorrento Therapeutics (SRNE 4.56%) jumped 10.6% on Thursday. The big gain came after the company announced that its COVI-STIX COVID-19 rapid diagnostic test received an official Emergency Use Authorization (EUA) and import license from the Mexican government.

Sorrento also stated that it's setting up a subsidiary to commercialize the test and future COVID products in Mexico.

So what

Sorrento announced earlier this month that COVI-STIX had received an EUA in Mexico. The company said at the time that it was preparing for the commercial launch of the test in the country. It might be at least a little surprising that the biotech stock rose so much today on what was in large part old news. 

Gloved hand holding a cotton swab in a person's mouth.

Image source: Getty Images.

But Sorrento's decision to establish its Sorrento Mexico Ltd. subsidiary underscores the drugmaker's commitment to succeed in the Mexican market. This good news, combined with a positive day for the overall stock market, propelled the biotech's shares higher.

Now what

Sorrento expects the first shipments of COVI-STIX will be delivered to Mexico in July. It could have more big news on the way soon: The company anticipates reporting results by the end of the third quarter of this year from two phase 2 studies evaluating abivertinib in treating hospitalized COVID patients.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.75 (4.56%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.